Group 1 - The core point of the article is that Sanbo Brain Science (301293.SZ) has confirmed that, apart from a previously completed intervention brain-computer interface surgery at its Fujian branch, there are no other surgeries currently being conducted within the group [1] Group 2 - The company has engaged with investors through an interactive platform to provide updates on its surgical activities [1] - The mention of the completed surgery indicates ongoing developments in the field of brain-computer interface technology [1] - The lack of additional surgeries may suggest a focus on consolidating existing operations before expanding further [1]

Core Viewpoint - The company, Sanbo Neuroscience, has confirmed that it has conducted one interventional brain-machine interface surgery at its Fujian facility, utilizing polyethylene glycol products, but specific product details are confidential due to collaboration agreements [1] Group 1 - The company has only performed one brain-machine interface surgery to date [1] - The surgery involved the use of polyethylene glycol, which meets national standards [1] - The specific product information used in the surgery is considered confidential among the collaborating parties [1]